- Lonza expands bioconjugation in Visp, adding two 1,200L suites for increased manufacturing capacity, addressing market demand, creating 200 jobs, operational by 2028.
Tue Nov 12 07:03:01 -2024 UTC– Lonza is expanding bioconjugation capabilities in Visp, Switzerland by adding two manufacturing suites to meet market demand for bioconjugates.
The expansion will create jobs and is set to be operational by 2028, with a focus on antibody-drug conjugates and other bioconjugates.
The investment aligns with Lonza’s emission reduction strategy and commitment to sustainability. The investment supports ADCs, sustainability, and waste reduction, enhancing Lonza’s bioconjugation services.
The expansion will create jobs and is set to be operational by 2028, with a focus on antibody-drug conjugates and other bioconjugates.
The investment aligns with Lonza’s emission reduction strategy and commitment to sustainability. The investment supports ADCs, sustainability, and waste reduction, enhancing Lonza’s bioconjugation services.
About Lisa